Successful use of gonadotropin-releasing hormone agonist in a patient with pulmonary endometriosis

T Koizumi, Tomonobu Koizumi, Koizumi T, Hiroshi Inagaki, Inagaki H, H Inagaki, Y Takabayashi, Takabayashi Y, Yasuki Takabayashi, K Kubo, Keishi Kubo, Kubo K
Respiration; international review of thoracic diseases · 1999 · vol. 66(6) , pp. 544–546 · doi:10.1159/000029433 · PMID:10575342 · W2082323105
Case report OA: closed CC0 ⤵ 21 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-18 ⓘ

A 26-year-old female with recurrent chest symptoms coinciding with menstruation, diagnosed as pulmonary endometriosis, was successfully treated with a GnRH agonist for six months and remained asymptomatic for 16 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A 26-year-old single female was admitted to hospital with recurrent chest pain, cough and hemoptysis. The symptoms developed 5 months before admission coinciding with menstruation. The disease was diagnosed as pulmonary endometriosis. She was treated with a long-acting gonadotropin-releasing hormone analogue (GnRH agonist; sustained-release leuprolide acetate, 3.75 mg/month, i.m.) for 6 months. She remained asymptomatic for 16 months with regular menstruation even after discontinuing the treatment. This indicates that the initial treatment of pulmonary endometriosis with a GnRH agonist is an acceptable medical alternative, especially in patients with a short duration of the disease from the onset of the chest symptoms.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Leuprolide Lung Diseases Adult Adult Delayed-Action Preparations Delayed-Action Preparations Drug Administration Schedule Drug Administration Schedule Endometriosis Endometriosis Female Female Follow-Up Studies Follow-Up Studies Humans Humans Leuprolide Leuprolide Lung Diseases Lung Diseases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Cited by (22)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T20:59:14.592962+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK